Duan 2018 — Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Citation: Duan D. (2018). “Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.” Molecular Therapy, 26(10), 2337–2356.
DOI: 10.1016/j.ymthe.2018.07.011
PMC: PMC6171037
File: ~/BookLibrary/incoming/Duan_2018_Systemic-AAV-micro-dystrophin-DMD_MolTher.pdf
Why This Matters for STRC
Dystrophin (~11 kb) faces the same problem as STRC (~6.9 kb) — both exceed single AAV capacity (~4.7 kb). DMD gene therapy has moved furthest in clinical translation. Duan’s micro-dystrophin work is the template for how to handle oversized genes via AAV.
Key Findings
- Micro-dystrophin approach: engineered miniaturized gene retaining critical functional domains
- Fits in single AAV (unlike dual-vector)
- Demonstrates systemic IV delivery is feasible for muscle
- Key domains retained: actin-binding (N-terminal), spectrin-like repeats 1,2,3,24, CR domain, CT domain
- Proof-of-concept for structural miniaturization as alternative to dual-vector splitting
Relevance to STRC
Two strategies for STRC oversized payload:
- Dual-vector split (Iranfar 2026 approach) — recombination in cochlea
- Mini-STRC — truncated but functional STRC, fits in single AAV
STRC functional domains: WD40 repeats (C-terminal, for TM attachment), N-terminal coiled-coil (for H-H links between stereocilia). A mini-STRC retaining these could work.
Clinical Translation Path
- Duan’s micro-dystrophin → Mendell 2020 Phase 1/2 trial → FDA accelerated approval pathway
- STRC likely follows same path: mouse model → NHP → IND → Phase 1/2
- Timeline estimate: 5-8 years from strong mouse data to Phase 1
Connections
- Iranfar_2026_STRC_dual_AAV [see-also]
- Mendell_2020_micro_dystrophin_clinical [see-also]
- Dual Vector AAV Strategy [see-also]
- STRC Gene Therapy Research [applies]
- Misha [applies]